Circulating VEGF as a biomarker for diagnosis of ovarian cancer: a systematic review and a meta-analysis
Open Access
- 1 May 2015
- journal article
- review article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. 8, 1075-1082
Abstract
VEGF is a frequently studied angiogenic factor in ovarian cancer (OC), and is considered to have an important role in the progression of OC. However, its diagnostic value has not been widely accepted because the conclusions are inconsistent and even conflicting. Therefore, we performed a meta-analysis to evaluate the diagnostic value of VEGF in OC. A systematic literature search was conducted using the PubMed, Cochrane Library, EMBASE, Chinese National Knowledge Infrastructure, and WANFANG databases for relevant published articles (the last search update was November 18, 2014). The diagnosis sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, and the summary receiver operating characteristic curves were pooled by Meta DiSc 1.4 software. A total of ten studies with 1,131 subjects were finally included in this meta-analysis. The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, and summary receiver operating characteristic curves were 0.67 (0.63–0.73), 0.78 (0.75–0.81), 3.08 (6.36–12.22), 0.39 (0.29–0.51), 9.10 (5.43–45.25), and 0.8175, respectively. Furthermore, to explore the sources of heterogeneity, we conducted subgroup analyses based on ethnicity and sample size. The diagnostic accuracy of VEGF was higher in an Asian population than in a Caucasian population. A similar finding was found in subgroups with the smaller sample size (<100 subjects). In conclusion, the present meta-analysis suggests that VEGF has moderate diagnostic accuracy for OC. Considering our limitations and the heterogeneity among our selected studies, larger, well-designed prospective and multicenter validation studies are needed to evaluate the diagnostic value of serum VEGF for OC.Keywords
This publication has 27 references indexed in Scilit:
- VEGF targets the tumour cellNature Reviews Cancer, 2013
- Predictive value of preoperative serum CCL2, CCL18, and VEGF for the patients with gastric cancerBMC Clinical Pathology, 2013
- Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cystsArchives of Gynecology and Obstetrics, 2013
- The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumorsJournal of Ovarian Research, 2013
- The genesis and evolution of high-grade serous ovarian cancerNature Reviews Cancer, 2010
- The biology of ovarian cancer: new opportunities for translationNature Reviews Cancer, 2009
- Expression of Vascular Endothelial Growth Factor (VEGF) and VEGF Receptors in Tumor Angiogenesis and MalignanciesIntegrative Cancer Therapies, 2005
- Multiplexed Immunobead-Based Cytokine Profiling for Early Detection of Ovarian CancerCancer Epidemiology, Biomarkers & Prevention, 2005
- Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test dataStatistics in Medicine, 2002
- Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patientsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1994